Targeting Tumors: How Dye Drug Conjugates Are Revolutionizing Cancer Treatment

In today’s episode, we sit down with Lyle Small to discuss cutting-edge methods of enhancing cancer treatments. Lyle is the founder and current CEO of Lahjavida, Inc., a cancer research firm focused on developing new cancer treatments. Known for their patented invention of a new cancer treatment, Lahjavida utilizes the tumor-targeting capabilities of NIR fluorescent dyes to work in conjunction with therapeutic agents – thus enhancing the effectiveness of a given therapy…

With an engineering degree from Cornell, Lyle has a diverse background in entrepreneurship. He served as the Founder and CEO of Chromatic Technologies, Inc. for more than 30 years, a company that pioneered several breakthroughs in the dye industry. Now, he leverages his extensive experience and knowledge to help in the battle against cancer.

What role does dye play in the identification and treatment of cancer? Join us now to find out for yourself!

Jump in to learn about:

• How Lyle’s experience has contributed to Lahjavida’s work.
• What dye chemists are, and their role in developing various medical technologies.
• What you need to know about Dye Drug Conjugates (DDCs).
• The holy grail of cancer treatment.

To follow along with Lyle’s work with Lahjavida, click here!

Episode also available on Apple Podcasts: http://apple.co/30PvU9

Podcast: Play in new window | Download | Embed